Developer docs
API playgroundTry for free, no card

Search company profiles

NovoCure

Full company profile

uuid0002a89

Namestring
NovoCure
Legal namestring
Novocure GmbH
Websiteurl
novocure.com
Company typeenum
Public
Founded yearint
2000
Short descriptiontext

NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a proprietary biophysical therapy delivered through three FDA-approved wearable devices (Optune Gio, Optune Lua, Optune Pax) for glioblastoma, non-small cell lung cancer, and pancreatic cancer patients. The company serves 4,620 active patients globally through direct field sales and reimbursement-based device distribution.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBaar, Switzerland
HQ citystring
Baar
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology medical devices, tumor treating fields, cancer therapy devices, glioblastoma treatment, solid tumor therapy
Industry3 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAIAL
Neuro-oncology
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Oncology Medical Devices
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1TTFields Medical Device Sales and Related Services
TypeHardware Sales
Description

Novocure generates revenue through the sale and rental of its TTFields therapy devices (Optune Gio, Optune Lua, Optune Pax) and related services. The company provides devices to patients through healthcare providers and directly, with revenue driven by active patient counts and reimbursement from Medicare, Medicare Advantage, and commercial payers.

finance.yahoo.com
2International Market Expansion
TypeHardware Sales
Description

Revenue growth driven by international expansion with active patient growth of 10% in Germany, 19% in France, and 29% in Japan. Japan approved National Health Insurance reimbursement for Optune Lua in March 2026, expanding commercial footprint in Asia-Pacific.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1Reimbursement-based pricing through Medicare, Medicare Advantage, and commercial insurance
ModelSubscriptionBilling cadencePay-as-you-go
Notes

Revenue generated through reimbursement from healthcare payers rather than direct patient payment. Company filed Corrective Action Plan with CMS following billing privilege revocation in January 2026, which was subsequently reinstated.

finance.yahoo.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Optune Gio
Description

Tumor Treating Fields device for glioblastoma

novocure.com
+2 more records
Core offering1 text field

NovoCure develops and commercializes Tumor Treating Fields (TTFields) therapy delivered via FDA-approved wearable medical devices that apply alternating electric fields to disrupt cancer cell division in solid tumors. The company sells three device brands—Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer, and Optune Pax for pancreatic cancer—used in combination with standard chemotherapy or immunotherapy. Revenue is generated through device sales and rental reimbursed by Medicare and commercial payers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 16.2 months vs 14.2 months median OS in pancreatic cancer (HR 0.82, p=0.037)
+4 more records
Product overview1 text field

NovoCure offers a portfolio of three FDA-approved wearable medical devices—Optune Gio, Optune Lua, and Optune Pax—all based on its proprietary Tumor Treating Fields (TTFields) platform technology. These portable, non-invasive devices deliver alternating electric fields at cancer-specific frequencies to disrupt cell division in solid tumors. Optune Gio targets glioblastoma, Optune Lua addresses non-small cell lung cancer, and Optune Pax treats pancreatic cancer, each used in combination with standard chemotherapy or immunotherapy regimens.

Product and service4 records
1Optune Gio
CategoryOncology Medical Device
Description

A wearable medical device that delivers Tumor Treating Fields (TTFields) to treat adult patients with newly diagnosed and recurrent glioblastoma. The device uses arrays placed on the scalp to deliver alternating electric fields that disrupt cancer cell division.

2Optune Lua
CategoryOncology Medical Device
Description

A wearable medical device delivering TTFields for non-small cell lung cancer (NSCLC). Approved for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent NSCLC who have progressed after platinum-based chemotherapy.

3Optune Pax
CategoryOncology Medical Device
Description

A portable, non-invasive device delivering TTFields to the abdomen for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. FDA-approved in February 2026 as the first new treatment for this indication in nearly 30 years.

4Tumor Treating Fields (TTFields) Therapy Platform
CategoryProprietary Therapy Platform
Description

The proprietary platform technology underlying NovoCure's commercial products. Uses alternating electric fields at specific frequencies (100-300 kHz) to exert physical forces on electrically charged components of cancer cells, disrupting mitosis and cell division while sparing healthy cells.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-05
Description

AACR-Novocure $350,000 TTFields grant for cancer research funding as part of OncoGrants roundup of cancer research funding opportunities.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-01-01
Description

Novocure joined New Hampshire Life Sciences as a founding member in January 2024. NHLS is the state's first industry-led life sciences association dedicated to improving patient lives and establishing New Hampshire as a leading life sciences hub. Novocure's North American headquarters has been in Portsmouth, NH since 2006.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-01-01
Description

Novo Nordisk also joined as a founding member of New Hampshire Life Sciences alongside Novocure. Both companies are global healthcare companies based in the region committed to championing New Hampshire's life sciences sector.

Strategic tierCoreTypeOthers
Description

Elevance Health secured first major payer coverage policy for Optune Pax within seven weeks of FDA approval, covering more than 30 million lives. This payer partnership is critical for patient access and commercial success of the pancreatic cancer therapy.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Swedish manufacturer of radiation therapy and radiosurgery equipment (Gamma Knife, linear accelerators) for cancer treatment. Elekta is a direct competitor in the oncology device space, treating similar solid tumor patient populations (including brain tumors) with a different but functionally adjacent modality (radiation vs. electric fields).

TypeDirect peer
Description

Now a Siemens Healthineers business, Varian is a global leader in radiation oncology devices and software. It competes directly with NovoCure for hospital and oncology clinic capital equipment budgets, treating similar solid tumor patient populations with a different modality.

TypeDirect peer
Description

US-based developer of robotic radiation therapy systems (CyberKnife, TomoTherapy) used to treat solid tumors. Accuray is comparable to NovoCure in oncology device commercialization model, hospital sales channels, and focus on hard-to-treat cancers including brain tumors.

TypeDirect peer
Description

Developer of MRI-guided radiation therapy systems (MRIdian) for cancer treatment. ViewRay targets similar oncology indications and patient populations as NovoCure, with both companies competing to displace or complement standard radiation and chemotherapy regimens.

5IBA (Ion Beam Applications)
TypeEmerging player
Description

Belgian company specializing in proton therapy solutions for cancer treatment. IBA competes in the advanced oncology device space with a focus on high-precision radiation delivery, partially overlapping with NovoCure's positioning in novel treatment modalities for solid tumors.

6Celsion Corporation
TypeEmerging player
Description

US oncology company developing novel treatment modalities including ThermoDox (heat-activated liposomal doxorubicin) for liver cancer and other solid tumors. Celsion is comparable as a smaller oncology company pursuing novel delivery technologies for difficult-to-treat cancers.

TypeBroad incumbent
Description

Global pharmaceutical leader with Keytruda (pembrolizumab) dominating the checkpoint inhibitor space. Merck competes with NovoCure indirectly through immunotherapy combinations in NSCLC and pancreatic cancer, where TTFields is being tested as a complementary modality.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Major oncology pharmaceutical company with Opdivo (nivolumab) and Yervoy (ipilimumab) leading its immuno-oncology franchise. BMS competes with NovoCure in NSCLC and other solid tumor indications where TTFields is being positioned as a complementary modality to checkpoint inhibitors.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NovoCure

Oncology Medical Devicesnovocure.com

NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a proprietary biophysical therapy delivered through three FDA-approved wearable devices (Optune Gio, Optune Lua, Optune Pax) for glioblastoma, non-small cell lung cancer, and pancreatic cancer patients. The company serves 4,620 active patients globally through direct field sales and reimbursement-based device distribution.

NovoCure firmographics

Firmographics
Name
NovoCure
Legal name
Novocure GmbH
Website
https://novocure.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
NovoCure is a global oncology company that develops and commercializes Tumor Treating Fields (TTFields), a proprietary biophysical therapy delivered through three FDA-approved wearable devices (Optune Gio, Optune Lua, Optune Pax) for glioblastoma, non-small cell lung cancer, and pancreatic cancer patients. The company serves 4,620 active patients globally through direct field sales and reimbursement-based device distribution.
Ownership category
akta.pro rank

NovoCure industry classification

Industry
Product category
Oncology Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAIAL
Neuro-oncology

Keywords

  • Oncology medical devices
  • Tumor treating fields
  • Cancer therapy devices
  • Glioblastoma treatment
  • Solid tumor therapy

Where NovoCure is headquartered

Location

Headquarters

HQ city
Baar
HQ country
Switzerland
HQ region
Europe

Offices10 records

Markets served

NovoCure business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. TTFields Medical Device Sales and Related Services: Novocure generates revenue through the sale and rental of its TTFields therapy devices (Optune Gio, Optune Lua, Optune Pax) and related services. The company provides devices to patients through healthcare providers and directly, with revenue driven by active patient counts and reimbursement from Medicare, Medicare Advantage, and commercial payers.
  2. International Market Expansion: Revenue growth driven by international expansion with active patient growth of 10% in Germany, 19% in France, and 29% in Japan. Japan approved National Health Insurance reimbursement for Optune Lua in March 2026, expanding commercial footprint in Asia-Pacific.

Pricing tiers

ModelBillingPrice
SubscriptionPay-as-you-goReimbursement-based pricing through Medicare, Medicare Advantage, and commercial insurance

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

NovoCure product offering

Product offering

Core offering

NovoCure develops and commercializes Tumor Treating Fields (TTFields) therapy delivered via FDA-approved wearable medical devices that apply alternating electric fields to disrupt cancer cell division in solid tumors. The company sells three device brands—Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer, and Optune Pax for pancreatic cancer—used in combination with standard chemotherapy or immunotherapy. Revenue is generated through device sales and rental reimbursed by Medicare and commercial payers.

Product overview

NovoCure offers a portfolio of three FDA-approved wearable medical devices—Optune Gio, Optune Lua, and Optune Pax—all based on its proprietary Tumor Treating Fields (TTFields) platform technology. These portable, non-invasive devices deliver alternating electric fields at cancer-specific frequencies to disrupt cell division in solid tumors. Optune Gio targets glioblastoma, Optune Lua addresses non-small cell lung cancer, and Optune Pax treats pancreatic cancer, each used in combination with standard chemotherapy or immunotherapy regimens.

Differentiator

Problem solved

Functional benefit

Brands

  • Optune Gio: Tumor Treating Fields device for glioblastoma
  • Optune Lua
  • Optune Pax

Products and services

  • Optune Gio A wearable medical device that delivers Tumor Treating Fields (TTFields) to treat adult patients with newly diagnosed and recurrent glioblastoma. The device uses arrays placed on the scalp to deliver alternating electric fields that disrupt cancer cell division.
  • Optune Lua A wearable medical device delivering TTFields for non-small cell lung cancer (NSCLC). Approved for concurrent use with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced or recurrent NSCLC who have progressed after platinum-based chemotherapy.
  • Optune Pax A portable, non-invasive device delivering TTFields to the abdomen for treating adult patients with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. FDA-approved in February 2026 as the first new treatment for this indication in nearly 30 years.
  • Tumor Treating Fields (TTFields) Therapy Platform The proprietary platform technology underlying NovoCure's commercial products. Uses alternating electric fields at specific frequencies (100-300 kHz) to exert physical forces on electrically charged components of cancer cells, disrupting mitosis and cell division while sparing healthy cells.

Quantifiable outcome

  • 16.2 months vs 14.2 months median OS in pancreatic cancer (HR 0.82, p=0.037)
  • +4 more outcomes

Companies that use NovoCure

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

NovoCure technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

NovoCure partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • AACR-Novocure TTFields GrantminorStrategic or Co-development Partner · 5 April 2026AACR-Novocure $350,000 TTFields grant for cancer research funding as part of OncoGrants roundup of cancer research funding opportunities.
  • New Hampshire Life Sciences (NHLS)minorGTM or Marketing Partner · 1 January 2024Novocure joined New Hampshire Life Sciences as a founding member in January 2024. NHLS is the state's first industry-led life sciences association dedicated to improving patient lives and establishing New Hampshire as a leading life sciences hub. Novocure's North American headquarters has been in Portsmouth, NH since 2006.
  • Novo NordiskminorGTM or Marketing Partner · 1 January 2024Novo Nordisk also joined as a founding member of New Hampshire Life Sciences alongside Novocure. Both companies are global healthcare companies based in the region committed to championing New Hampshire's life sciences sector.
  • Elevance HealthcoreOthersElevance Health secured first major payer coverage policy for Optune Pax within seven weeks of FDA approval, covering more than 30 million lives. This payer partnership is critical for patient access and commercial success of the pancreatic cancer therapy.

Scale indicators13 records

Recent moves8 records

Expansion highlights5 records

NovoCure competitors and assessment

Company assessment

Direct peers

  • Elekta: Swedish manufacturer of radiation therapy and radiosurgery equipment (Gamma Knife, linear accelerators) for cancer treatment. Elekta is a direct competitor in the oncology device space, treating similar solid tumor patient populations (including brain tumors) with a different but functionally adjacent modality (radiation vs. electric fields).
  • Varian Medical Systems: Now a Siemens Healthineers business, Varian is a global leader in radiation oncology devices and software. It competes directly with NovoCure for hospital and oncology clinic capital equipment budgets, treating similar solid tumor patient populations with a different modality.
  • Accuray Incorporated: US-based developer of robotic radiation therapy systems (CyberKnife, TomoTherapy) used to treat solid tumors. Accuray is comparable to NovoCure in oncology device commercialization model, hospital sales channels, and focus on hard-to-treat cancers including brain tumors.
  • ViewRay Technologies: Developer of MRI-guided radiation therapy systems (MRIdian) for cancer treatment. ViewRay targets similar oncology indications and patient populations as NovoCure, with both companies competing to displace or complement standard radiation and chemotherapy regimens.

Emerging players

  • IBA (Ion Beam Applications): Belgian company specializing in proton therapy solutions for cancer treatment. IBA competes in the advanced oncology device space with a focus on high-precision radiation delivery, partially overlapping with NovoCure's positioning in novel treatment modalities for solid tumors.
  • Celsion Corporation: US oncology company developing novel treatment modalities including ThermoDox (heat-activated liposomal doxorubicin) for liver cancer and other solid tumors. Celsion is comparable as a smaller oncology company pursuing novel delivery technologies for difficult-to-treat cancers.

Broad incumbents

  • Merck & Co. Global pharmaceutical leader with Keytruda (pembrolizumab) dominating the checkpoint inhibitor space. Merck competes with NovoCure indirectly through immunotherapy combinations in NSCLC and pancreatic cancer, where TTFields is being tested as a complementary modality.
  • Bristol-Myers Squibb: Major oncology pharmaceutical company with Opdivo (nivolumab) and Yervoy (ipilimumab) leading its immuno-oncology franchise. BMS competes with NovoCure in NSCLC and other solid tumor indications where TTFields is being positioned as a complementary modality to checkpoint inhibitors.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

NovoCure social profiles

Digital presence

NovoCure compliance and trust

Trust signal

Compliance4 records

NovoCure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NovoCure leadership team

Management profile

Number of profiles

Profiles10 records

NovoCure subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

NovoCure funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NovoCure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovoCure

What does NovoCure do?

NovoCure develops and commercializes Tumor Treating Fields (TTFields) therapy delivered via FDA-approved wearable medical devices that apply alternating electric fields to disrupt cancer cell division in solid tumors. The company sells three device brands—Optune Gio for glioblastoma, Optune Lua for non-small cell lung cancer, and Optune Pax for pancreatic cancer—used in combination with standard chemotherapy or immunotherapy. Revenue is generated through device sales and rental reimbursed by Medicare and commercial payers.

Is NovoCure a public or private company?

NovoCure is a public company. It is classified as public and is currently operating.

When was NovoCure founded?

NovoCure was founded in 2000. It employs 1,001 to 5,000 people.

Where is NovoCure based?

NovoCure is headquartered in Baar, Switzerland, in the Europe region.

How does NovoCure make money?

Two revenue lines are on record. TTFields Medical Device Sales and Related Services are the primary driver. The others are international Market Expansion.

Who are NovoCure's main competitors?

Direct peers on record are Elekta, Varian Medical Systems, Accuray Incorporated and ViewRay Technologies. Emerging players are IBA (Ion Beam Applications) and Celsion Corporation. Broad incumbents are Merck & Co. and Bristol-Myers Squibb.

Does NovoCure have an API?

No public API is recorded for NovoCure.

What industry is NovoCure in?

NovoCure's product category is Oncology Medical Devices. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAKAFAB, Medical Oncology. Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogJAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic CancerJAMA Network Open published secondary analysis of the Phase 3 PANOVA-3 trial of Novocure's Tumor Treating Fields with gemcitabine and nab-paclitaxel for pancreatic cancer. The trial met its primary endpoint, showing improved median overall survival, and the secondary analysis found statistically significant and clinically meaningful benefits in pain and quality-of-life measures.FinancialContent Business PageJAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic CancerNovocure announced that JAMA Network Open published secondary analysis data from the Phase 3 PANOVA-3 trial of Tumor Treating Fields with gemcitabine and nab-paclitaxel in unresectable pancreatic adenocarcinoma. The trial met its primary endpoint, showing improved median overall survival, and the secondary analysis found statistically significant and clinically meaningful benefits in pain and quality of life measures.Stock TitanNovocure PANOVA-3 analysis finds pain and quality-of-life gainsNovocure announced JAMA Network Open published secondary analysis of the Phase 3 PANOVA-3 trial, which evaluated TTFields therapy with gemcitabine and nab-paclitaxel for unresectable pancreatic adenocarcinoma. The trial met its primary endpoint with improved median overall survival, and secondary analysis showed statistically significant and clinically meaningful benefits in pain and quality-of-life measures.TradingViewNovocure (NVCR) Reports Significant Quality-Of-Life and Pain Benefits in PANOVA-3Novocure reported statistically significant and clinically meaningful benefits across multiple quality-of-life and pain measures in a prespecified secondary analysis of Phase 3 PANOVA-3 data. The trial had previously met its primary endpoint of improved median overall survival, with no new safety signals reported.TradingViewJAMA Network Open Publishes Quality of Life and Pain Outcomes Data from Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields for Pancreatic CancerNovocure announced that JAMA Network Open published secondary analysis of the Phase 3 PANOVA-3 trial, which evaluated Tumor Treating Fields with gemcitabine and nab-paclitaxel versus chemotherapy alone in unresectable pancreatic adenocarcinoma. The trial met its primary endpoint with improved median overall survival, and the secondary analysis showed statistically significant, clinically meaningful benefits in pain and quality-of-life measures.Simply Wall StDid FDA Rejection Of Optune Mya Just Shift NovoCure Stock Narrative?The FDA issued a Not Approvable Letter for NovoCure's Optune Mya PMA application for brain metastases, citing uncertainty over clinical benefit. The setback heightens execution risk on other TTFields devices, with NovoCure projecting US$1.2b revenue and US$78.3m earnings by 2029. The letter shifts focus to Optune Pax and other indications.Defense WorldLADENBURG THALM/SH SH Issues Positive Forecast for NovoCure (NASDAQ:NVCR) Stock PriceLadenburg Thalmann raised its NovoCure price target to $31 from $27, keeping a buy rating. NovoCure reported Q3 EPS of -$0.09, beating estimates of -$0.23, with revenue up 15.7% year-over-year. The FDA declined to approve Optune Mya, a wearable device for brain metastases.The Motley FoolFDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.The FDA issued a not approvable letter for NovoCure's Optune Mya, citing uncertainty about clinical benefit. NovoCure's stock fell 6.9% on the news, and the company is evaluating a path to approval without further studies. The rejection adds to investor concerns about the company's profitability and Pax rollout timing.The Motley FoolFDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.The FDA issued a not approvable letter for NovoCure's Optune Mya, citing uncertainty about clinical benefit, after the device met its primary endpoint but fell short of secondary ones. NovoCure's stock fell 6.94% on the news, and the company is evaluating whether to pursue approval without further studies.Seeking AlphaNovoCure denied FDA approval of Optune Mya for brain metastasesThe US FDA issued NovoCure a Not Approvable Letter for its Optune Mya device for treating brain metastases from non-small cell lung cancer after stereotactic radiation. The agency cited uncertainty around the degree of clinical benefit.